Why rare cancers need a different approach
One in two people get cancer.
One in five cancer patients is diagnosed with a rare form of the disease.
But while oncology has advanced rapidly, traditional research models still fall short for rare cancer patients, because they weren’t built for this kind of complexity.
Rare cancers are often biologically diverse and highly heterogeneous. That means: distinct cell populations between tumors in different patients, but also within the same tumor. Small patient groups, complex biology and scattered infrastructure make it difficult to run efficient, scalable clinical trials.
At Yamicc, we believe this must change. We’re building a new platform for rare cancer research where all patients have access, infrastructure is shared, data flows across studies and hospitals and collaboration is the norm. Faster, better data, more efficient and eventually cheaper trials, all with the patient in mind.
You and Me in Curing Cancer isn’t just a message, we need a new mindset to create better opportunities for these patients. Are you in?
